TRASTUZUMAB ASSOCIATED LEFT VENTRICULAR DYSFUNCTION: CAN THE NEED FOR TREATMENT INTERRUPTION BE PREDICTED AND DOES INTERRUPTION AFFECT CARDIOVASCULAR OR ONCOLOGIC OUTCOMES?